Critical questions in ovarian cancer research and treatment

Report of an American Association for Cancer Research Special Conference

Robert C. Bast, Ursula A. Matulonis, Anil K. Sood, Ahmed A. Ahmed, Adaobi E. Amobi, Frances R. Balkwill, Monicka Wielgos-Bonvallet, David D.L. Bowtell, James D. Brenton, Joan S. Brugge, Robert L. Coleman, Giulio F. Draetta, Kai Doberstein, Ronny I. Drapkin, Mark A. Eckert, Robert P. Edwards, Kevin M. Elias, Darren Ennis, Andrew Futreal, David M. Gershenson & 23 others Roger A. Greenberg, David G. Huntsman, Jennifer Xiao Ye Ji, Elise C. Kohn, Claudia Iavarone, Ernst R. Lengyel, Douglas A. Levine, Christopher J. Lord, Zhen Lu, Gordon B. Mills, Francesmary Modugno, Brad H. Nelson, Kunle Odunsi, Jessica A. Pilsworth, Robert K. Rottapel, Daniel J. Powell, Li Shen, Ie Ming Shih, David R. Spriggs, Josephine Walton, Kaiyang Zhang, Rugang Zhang, Lee Zou

Research output: Contribution to journalComment/debate

Abstract

Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on “Critical Questions in Ovarian Cancer Research and Treatment” was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.

Original languageEnglish (US)
Pages (from-to)1963-1972
Number of pages10
JournalCancer
Volume125
Issue number12
DOIs
StatePublished - Jun 15 2019

Fingerprint

Ovarian Neoplasms
Poly Adenosine Diphosphate Ribose
Drug Therapy
Platinum
Drug Resistance
Immunotherapy
Neoplasms
Patient Care
Therapeutics
Research Personnel
Research
Pharmaceutical Preparations

Keywords

  • drug resistance
  • early detection
  • heterogeneity
  • immunotherapy
  • metabolism
  • microenvironment
  • ovarian cancer
  • PARP inhibitors
  • prevention

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bast, R. C., Matulonis, U. A., Sood, A. K., Ahmed, A. A., Amobi, A. E., Balkwill, F. R., ... Zou, L. (2019). Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer, 125(12), 1963-1972. https://doi.org/10.1002/cncr.32004

Critical questions in ovarian cancer research and treatment : Report of an American Association for Cancer Research Special Conference. / Bast, Robert C.; Matulonis, Ursula A.; Sood, Anil K.; Ahmed, Ahmed A.; Amobi, Adaobi E.; Balkwill, Frances R.; Wielgos-Bonvallet, Monicka; Bowtell, David D.L.; Brenton, James D.; Brugge, Joan S.; Coleman, Robert L.; Draetta, Giulio F.; Doberstein, Kai; Drapkin, Ronny I.; Eckert, Mark A.; Edwards, Robert P.; Elias, Kevin M.; Ennis, Darren; Futreal, Andrew; Gershenson, David M.; Greenberg, Roger A.; Huntsman, David G.; Ji, Jennifer Xiao Ye; Kohn, Elise C.; Iavarone, Claudia; Lengyel, Ernst R.; Levine, Douglas A.; Lord, Christopher J.; Lu, Zhen; Mills, Gordon B.; Modugno, Francesmary; Nelson, Brad H.; Odunsi, Kunle; Pilsworth, Jessica A.; Rottapel, Robert K.; Powell, Daniel J.; Shen, Li; Shih, Ie Ming; Spriggs, David R.; Walton, Josephine; Zhang, Kaiyang; Zhang, Rugang; Zou, Lee.

In: Cancer, Vol. 125, No. 12, 15.06.2019, p. 1963-1972.

Research output: Contribution to journalComment/debate

Bast, RC, Matulonis, UA, Sood, AK, Ahmed, AA, Amobi, AE, Balkwill, FR, Wielgos-Bonvallet, M, Bowtell, DDL, Brenton, JD, Brugge, JS, Coleman, RL, Draetta, GF, Doberstein, K, Drapkin, RI, Eckert, MA, Edwards, RP, Elias, KM, Ennis, D, Futreal, A, Gershenson, DM, Greenberg, RA, Huntsman, DG, Ji, JXY, Kohn, EC, Iavarone, C, Lengyel, ER, Levine, DA, Lord, CJ, Lu, Z, Mills, GB, Modugno, F, Nelson, BH, Odunsi, K, Pilsworth, JA, Rottapel, RK, Powell, DJ, Shen, L, Shih, IM, Spriggs, DR, Walton, J, Zhang, K, Zhang, R & Zou, L 2019, 'Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference', Cancer, vol. 125, no. 12, pp. 1963-1972. https://doi.org/10.1002/cncr.32004
Bast, Robert C. ; Matulonis, Ursula A. ; Sood, Anil K. ; Ahmed, Ahmed A. ; Amobi, Adaobi E. ; Balkwill, Frances R. ; Wielgos-Bonvallet, Monicka ; Bowtell, David D.L. ; Brenton, James D. ; Brugge, Joan S. ; Coleman, Robert L. ; Draetta, Giulio F. ; Doberstein, Kai ; Drapkin, Ronny I. ; Eckert, Mark A. ; Edwards, Robert P. ; Elias, Kevin M. ; Ennis, Darren ; Futreal, Andrew ; Gershenson, David M. ; Greenberg, Roger A. ; Huntsman, David G. ; Ji, Jennifer Xiao Ye ; Kohn, Elise C. ; Iavarone, Claudia ; Lengyel, Ernst R. ; Levine, Douglas A. ; Lord, Christopher J. ; Lu, Zhen ; Mills, Gordon B. ; Modugno, Francesmary ; Nelson, Brad H. ; Odunsi, Kunle ; Pilsworth, Jessica A. ; Rottapel, Robert K. ; Powell, Daniel J. ; Shen, Li ; Shih, Ie Ming ; Spriggs, David R. ; Walton, Josephine ; Zhang, Kaiyang ; Zhang, Rugang ; Zou, Lee. / Critical questions in ovarian cancer research and treatment : Report of an American Association for Cancer Research Special Conference. In: Cancer. 2019 ; Vol. 125, No. 12. pp. 1963-1972.
@article{03075953b3a341bea544b71aea29579e,
title = "Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference",
abstract = "Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on “Critical Questions in Ovarian Cancer Research and Treatment” was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.",
keywords = "drug resistance, early detection, heterogeneity, immunotherapy, metabolism, microenvironment, ovarian cancer, PARP inhibitors, prevention",
author = "Bast, {Robert C.} and Matulonis, {Ursula A.} and Sood, {Anil K.} and Ahmed, {Ahmed A.} and Amobi, {Adaobi E.} and Balkwill, {Frances R.} and Monicka Wielgos-Bonvallet and Bowtell, {David D.L.} and Brenton, {James D.} and Brugge, {Joan S.} and Coleman, {Robert L.} and Draetta, {Giulio F.} and Kai Doberstein and Drapkin, {Ronny I.} and Eckert, {Mark A.} and Edwards, {Robert P.} and Elias, {Kevin M.} and Darren Ennis and Andrew Futreal and Gershenson, {David M.} and Greenberg, {Roger A.} and Huntsman, {David G.} and Ji, {Jennifer Xiao Ye} and Kohn, {Elise C.} and Claudia Iavarone and Lengyel, {Ernst R.} and Levine, {Douglas A.} and Lord, {Christopher J.} and Zhen Lu and Mills, {Gordon B.} and Francesmary Modugno and Nelson, {Brad H.} and Kunle Odunsi and Pilsworth, {Jessica A.} and Rottapel, {Robert K.} and Powell, {Daniel J.} and Li Shen and Shih, {Ie Ming} and Spriggs, {David R.} and Josephine Walton and Kaiyang Zhang and Rugang Zhang and Lee Zou",
year = "2019",
month = "6",
day = "15",
doi = "10.1002/cncr.32004",
language = "English (US)",
volume = "125",
pages = "1963--1972",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Critical questions in ovarian cancer research and treatment

T2 - Report of an American Association for Cancer Research Special Conference

AU - Bast, Robert C.

AU - Matulonis, Ursula A.

AU - Sood, Anil K.

AU - Ahmed, Ahmed A.

AU - Amobi, Adaobi E.

AU - Balkwill, Frances R.

AU - Wielgos-Bonvallet, Monicka

AU - Bowtell, David D.L.

AU - Brenton, James D.

AU - Brugge, Joan S.

AU - Coleman, Robert L.

AU - Draetta, Giulio F.

AU - Doberstein, Kai

AU - Drapkin, Ronny I.

AU - Eckert, Mark A.

AU - Edwards, Robert P.

AU - Elias, Kevin M.

AU - Ennis, Darren

AU - Futreal, Andrew

AU - Gershenson, David M.

AU - Greenberg, Roger A.

AU - Huntsman, David G.

AU - Ji, Jennifer Xiao Ye

AU - Kohn, Elise C.

AU - Iavarone, Claudia

AU - Lengyel, Ernst R.

AU - Levine, Douglas A.

AU - Lord, Christopher J.

AU - Lu, Zhen

AU - Mills, Gordon B.

AU - Modugno, Francesmary

AU - Nelson, Brad H.

AU - Odunsi, Kunle

AU - Pilsworth, Jessica A.

AU - Rottapel, Robert K.

AU - Powell, Daniel J.

AU - Shen, Li

AU - Shih, Ie Ming

AU - Spriggs, David R.

AU - Walton, Josephine

AU - Zhang, Kaiyang

AU - Zhang, Rugang

AU - Zou, Lee

PY - 2019/6/15

Y1 - 2019/6/15

N2 - Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on “Critical Questions in Ovarian Cancer Research and Treatment” was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.

AB - Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on “Critical Questions in Ovarian Cancer Research and Treatment” was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.

KW - drug resistance

KW - early detection

KW - heterogeneity

KW - immunotherapy

KW - metabolism

KW - microenvironment

KW - ovarian cancer

KW - PARP inhibitors

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=85062528733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062528733&partnerID=8YFLogxK

U2 - 10.1002/cncr.32004

DO - 10.1002/cncr.32004

M3 - Comment/debate

VL - 125

SP - 1963

EP - 1972

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -